Navigation Links
Vaccines preventing pneumococcal disease protect African children with sickle-cell disease
Date:4/28/2010

WASHINGTON, DC A new study released this week in The Lancet Infectious Diseases finds that African children who contract pneumococcus a bacterial infection that causes pneumonia, meningitis and sepsis are 36 times as likely to have sickle-cell disease, a blood disorder prevalent in African children that increases the risk for infectious diseases and early death. The study underscores the critical need for use of pneumococcal conjugate vaccines (PCV) among populations predisposed to sickle-cell disease, most notably those in sub-saharan Africa.

"Our findings clearly show that African children with sickle-cell disease are at increased risk of bacterial illness compared with their peers without sickle-cell disease, with the pneumococcus being of particular concern," said Dr. Keith P. Klugman, contributing author and professor and William H. Foege Chair in Global Health at the Rollins School of Public Health.

Africa is home to the vast majority of the world's sickle-cell disease cases. Sickle-cell disease is inherited by a child from both parents and is caused by abnormal hemoglobin, a blood protein that distorts the shape of red blood cells and delivers less oxygen to tissues. The disease weakens the immune system and puts its victims at risk for serious bacterial infection and childhood death. Data examined from studies in the Democratic Republic of the Congo, Nigeria, Kenya and Senegal countries with the highest sickle-cell disease burden clearly demonstrate an increased risk of serious bacterial infection, especially invasive pneumococcal disease, in African children with sickle-cell disease.

"In combination with early diagnosis and treatment of sickle-cell disease, routine, country-wide immunization against pneumococcus is the best strategy to improve quality of life for all African children, particularly those with sickle-cell disease," said Orin Levine, contributing author, executive director of the International Vaccine Access Center (IVAC) at The Johns Hopkins Bloomberg School of Public Health and co-chair of the Pneumococcal Awareness Council of Experts (PACE). "Millions of lives can be saved by improving access to pneumococcal conjugate vaccines."

One-third of all indigenous inhabitants of Sub-Saharan Africa carry the sickle cell gene, and approximately, 230,000 African children are born with sickle-cell disease each year. Because routine access to medical care is out of reach for many children in the region, the average life expectancy for those afflicted with sickle cell disease in Africa is less than 20 years. In many developed countries where comprehensive care including pneumococcal vaccination and aggressive treatment are available, life-expectancy for sickle cell patients is 45-55 years. Since PCV was first introduced in 2000 in the United States, invasive pneumococcal infections in children with sickle-cell disease declined 68 percent in children under 10 and by 90 percent in children under five.

"The one-two punch of sickle-cell disease coupled with pneumococcal disease is devastating in Africa making protecting Africa's children through vaccination an urgent priority," said Ciro A. de Quadros executive vice president of the Sabin Vaccine Institute and co-chair of PACE. "We urge the leaders of African countries to make routine vaccination against pneumococcal disease a priority."

Pneumococcal disease is a bacterial infection that causes life-threatening pneumonia, meningitis and sepsis. Every year, pneumococcal disease takes the lives of nearly 1.6 million people, nearly half of whom are young children in the developing world, where vaccines to prevent the disease are not yet in widespread use. The lack of access in these countries has been due primarily to obstacles in awareness, policy guidance and available financing for low-income countries.

Safe and effective vaccines currently exist to prevent pneumococcal deaths. In 2006, the World Health Organization (WHO) recommended that all countries include PCV in their national immunization programs, especially in countries where childhood mortality is high. The WHO recommendation guides country policy-making on the prioritization of measures to address childhood pneumococcal disease.


'/>"/>

Contact: Mala Persaud
Mala.Persaud@gmmb.com
202-572-2980
Johns Hopkins University Bloomberg School of Public Health
Source:Eurekalert

Related biology news :

1. GEN reports on the promise of DNA vaccines
2. Major breakthrough may pave the way for therapeutic vaccines
3. Bug barcode readers hold out promise of universal vaccines
4. Pitt researchers find promising candidate protein for cancer prevention vaccines
5. Study shows cancer vaccines led to long-term survival for patients with metastatic melanoma
6. Princeton teams analysis of flu virus could lead to better vaccines
7. New evidence explains poor infant immune response to certain vaccines, says MU researcher
8. Vaccines and autism: Many hypotheses, but no correlation
9. New type of vaccines deliver stronger and faster immune response
10. Syracuse University partners with Serum Institute of India to develop vaccines for children
11. Prostate cancer vaccines more effective with hormone therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... MELBOURNE, Australia , March 2, 2017 ... Therapeutics Ltd (ASX: CYP), has signed an agreement ... researchers from the Monash Biomedicine Discovery Institute and Department ... , to conduct a further preclinical study to support ... the treatment of asthma.  Asthma is ...
(Date:2/28/2017)... 28, 2017   Acuant , a leading provider ... significant enhancements to new and core technologies building upon ... include mobile and desktop Acuant FRM TM facial ... a real time manual review of identity documents by ... the fastest and most accurate capture software to streamline ...
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ... Iris-Scan, wird seine erstklassige biometrische Lösung zur ... 835 mit X16 LTE auf dem Mobile ... März) am Qualcomm-Stand in Halle 3, Stand ... beinhaltet die Sicherheitsplattform Qualcomm Haven™ – eine ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... 2017  The global market for clinical laboratory ... a new report from Kalorama Information.  In addition ... to evaluate disease progression, monitor drug treatment and ... The healthcare market research firm,s report, ... overview of the medical laboratory industry and the ...
(Date:3/27/2017)... DIEGO , March 27, 2017  Trovagene, Inc. ... that its Chief Executive Officer, Bill Welch , ... April 4, 2017 at 9:00 AM EDT at the ... .  Bill Welch, and Chief Scientific Officer, Mark ... with investors during the conference.   The presentation ...
(Date:3/24/2017)... DUBLIN , Mar. 24, 2017 Research ... Stem Cell (hESC) Research - Global Strategic Business Report" report ... ... Cell (hESC) Research in US$ Million. Annual estimates and forecasts are ... are derived from primary and secondary research. The ...
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed president, Jake Lubinski, describes ... characteristics when deformed, which is identical to how the human discs work to ... and return to its natural state along a hysteresis curve, exactly like a ...
Breaking Biology Technology: